Stručni članak

TUE U SRBIJI - SA POSEBNIM OSVRTOM NA PRIMENU GLIKOKORTIKOSTEROIDA
Marija Anđelković, Nenad Dikić
Antidoping agencija Republike Srbije

Apstrakt

TUE (Therapeutical Use Exemption) ili izuzeće radi terapeutske upotrebe se zahteva kada sportista mora da uzima lek sa Liste zabranjenih supstanci. U proteklih godinu i po dana, Antidoping agencija Republike Srbije (ADAS) registrovala je 33 TUE, od čega su 30 bila ATUE - skraćeni TUE za nesistemske glikokortikoide i inhalatorne beta-2-agoniste (formoterol, salbutamol, salmeterol i terbutalin). Grupa bolesti za koje se najviše tražilo terapeutsko izuzeće su skeletnomuskularni poremećaji (48%), a na drugom mestu je astma (30%). Lekovi sa zabranjene liste za koje se najčešće traži TUE su glikokortikosteroidi (63%), i inhalatorni beta-2-agonisti (36%). Najzastupljeniji glikokortikosteroid kod nas je depo preparat Diprofos, koji je najčešće aplikovan periartikularno sa diskutabilnom efikasnošću i rizikom za sistemsko širenje. U radu će biti prikazani interesantni slučajevi iz naše i međunarodne prakse. Od 2009. godine postoje izmene tako da će standardni TUE važiti za sve lekove osim za nesistemske i inhalatorne glikokortikosteroide za koje će se popunjavati samo Deklaracija o upotrebi.

Abstract

TUE (Therapeutical Use Exemption) is required before athlete wants to use the substances from Prohibited List. In last eighteen months Antidoping agency of Serbia (ADAS) registered 33 TUE proces. From this number, 30 was ATUE (Abbreviated TUE) which is required for beta-2-agonist by inhalation and glucocorticosteroids by non-systemic routes. The most common medical disorder in TUE proces in Serbia is musculosceletal conditions (48%), and on second place is asthma (30%). The most presented prohibited supstances are glucocorticosteroids (63%) and beta-2 agonists administered by inhalation (36%). Periarticular administered Diprophos is the most frequently used glucocorticosteroid, with a question is this route of administration strictly local and effective. Certain case studies of national and international federations will be presented in this article. In 2009. year there will be some changes in TUE process. For non-systemic and inhalative glucocorticosteroids, Declaration of Use is introduced, instead formerly ATUE, while inhalative beta-2 agonists required full TUE process.

To download PDF (Adobe Acrobat) version, click here